The hypoglycemic effect of glibornuride (Glutril), a new derivate of the hypoglycemic sulfonylureas, was studied on 97 diabetics registered at the Diabetic Clinic of Seoul National University Hospital. From the observation of the effect after administering for 1-19 months, average 4.8 months, to the almost not or poorly controlled maturity-onset diabetic patients, the following results were obtained:
1. Glibornuride was given to 62 cases who had been treated with dietary regimen alone and the excellent or good control was obtained in 37 cases (60%).
2. Out of 30 cases who had been treated with other sulfonylurea derivates, 12 cases (40%) showed excellent or good control.
3. Glibornuride treatment in 5 cases who had been treated with less than 20 units of NPH insulin, resulted in excellent or good control in 3 cases (60%).
4. The idfluence of age, body weight, and duration of disease was studied. According to the results, difference of age showed no remarkable influence on the effect of glibornuride, but relatively better results were obtained in the group of obese patients, namely 80% of them showed excellent or good control. The shorter the duration of disease, the better the results.
5. The required period to show excellent or good control was 1-20 weeks, average 3-7 weeks, and the higher the fasting blood sugar,level before glibornuride administration, the longer the required period. At least 4-8 weeks seem to be necessary to extimate the effect of this agent.
6. During this trial there were 5 cases (5%) of primary failure and 3 cases (3%) of relative secondary failure among the relatively severe patients with long diabetic duration.
7. As the side effects, hypoglycemic symptoms, epigastric discomfort, nausea, fatigability or indigestion, all transient and mild, were seen respectively in 7 cases (7.2%), but there was no case who had to discontinue this agent.
Considering strong hypoglycemic effect and absence of any remarkable side effects and toxidity during the clinic studies, we can conclude that glibornuride is thought to be an useful agent in long term therapy of diabetes in the suitable indication.
|